Calithera Biosciences, Inc. CALA was a big mover last session, as its shares rose almost 47% on the day. The move came after the company reported a global collaboration and licensing agreement with Incyte Corp. INCY. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $3.60 to $4.90 in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days while the Zacks Consensus Estimate also moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Calithera Biosciences currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Calithera Biosciences, Inc. Price
Calithera Biosciences, Inc. Price | Calithera Biosciences, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment